SGLT2 Inhibitors and Peripheral Vascular Events
- 12 August 2022
- journal article
- review article
- Published by Elsevier in Heart Failure Clinics
- Vol. 18 (4) , 609-623
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 InhibitorCirculation, 2018
- Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort studyDiabetes, Obesity and Metabolism, 2017
- Amputation Rates, Mortality, and Pre-operative Comorbidities in Patients Revascularised for Intermittent Claudication or Critical Limb Ischaemia: A Population Based StudyEuropean Journal of Vascular and Endovascular Surgery, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical TrialsAdvances in Therapy, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysisThe Lancet, 2013
- Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patientsPharmacoepidemiology and Drug Safety, 2004
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)The Lancet, 2000